All In Biotech

Drug Trial Radar · NCT03655483

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

A Single Arm,Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

85

Planned (sponsor's estimate)

Start

Aug 24, 2018

Primary completion

Apr 11, 2021

Study completion Apr 11, 2022

Sponsor

Sponsor type
Industry
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with refractory cHL. Patients will be treated with GLS-010

Conditions

  • Classical Hodgkin's Lymphoma

Interventions

  • GLS-010Drug

    Full-human anti-pd-1 monoclonal antibodies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: 2 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, China

  • Guizhou Cancer Hospital

    Guiyang, Guizhou, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.